Sanofi

We chase the miracles of science so you can chase your dreams.

Learn more

Our Latest Articles

n overview of how Sanofi’s Blood-Brain Barrier (BBB) Shuttle delivers a medicine into the brain.

AI in Healthcare

June 30, 2026

How Sanofi’s Blood-Brain Barrier Shuttle is Rewriting the Script for Rare Diseases

A technologist, wearing purple glove and safety glasses performing structural analysis by HDX-MS, handling samples with precision.

First quarter 2026

Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.

Two women in black wetsuits standing on a beach with a surfboard, ready for surfing

The Power of Chasing A Dream

Every day, we chase the miracles of science to improve people’s lives. We apply our deep understanding of the immune system to develop breakthrough innovations in medicines and vaccines so you can focus on what matters most, chasing your dreams. If you’re chasing your dreams, remember... you’re not alone. We’re right beside you

 

People Stories

We’re proud to spotlight those who inspire us to keep going further in the work we do.

A woman wearing a black wetsuit holds a surfboard under blue skies and sunshine while looking out to the horizon with a hopeful and determined expression.​

Céline, living with secondary progressive multiple sclerosis

France

We are an R&D driven, AI-powered biopharmaceutical company committed to improving people’s lives and delivering compelling growth

About Us

Who We Are

We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.

Our Pipeline

5

Therapeutic areas

77

Compounds in clinical development

21

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases


June 30, 2026
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

June 25, 2026
Press Release: Sanofi Foundation opens new chapter centered on future generations

June 23, 2026
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

June 23, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses